

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS† - 99.4%					
BIOTECHNOLOGY - 75.8%					
Amgen, Inc.	14,717	\$ 4,585,081	Krystal Biotech, Inc.*	2,520	\$ 454,356
Gilead Sciences, Inc.	37,674	4,221,372	Ideaya Biosciences, Inc.*	26,912	440,819
Vertex Pharmaceuticals, Inc.*	7,994	3,875,651	Immunovant, Inc.*	24,485	418,449
Regeneron Pharmaceuticals, Inc.	5,077	3,219,986	Celldex Therapeutics, Inc.*	21,816	395,960
Corteva, Inc.	43,585	2,742,804	Iovance Biotherapeutics, Inc.*	118,443	394,415
Alnylam Pharmaceuticals, Inc.*	9,122	2,463,122	Dyne Therapeutics, Inc.*	36,025	376,822
BeiGene Ltd. ADR*	7,699	2,095,437	Novavax, Inc.* ¹	55,748	357,345
Biogen, Inc.*	13,038	1,784,120	Intellia Therapeutics, Inc.* ¹	41,511	295,143
Royalty Pharma plc — Class A	49,676	1,546,414	Geron Corp.*	159,425	253,486
United Therapeutics Corp.*	4,929	1,519,463	Total Biotechnology		66,097,268
Insmed, Inc.*	19,715	1,504,057	PHARMACEUTICALS - 18.6%		
BioMarin Pharmaceutical, Inc.*	20,691	1,462,647	AbbVie, Inc.	32,779	6,867,856
Intra-Cellular Therapies, Inc.*	11,075	1,461,014	AstraZeneca plc ADR	25,870	1,901,445
Illumina, Inc.*	17,445	1,384,086	Neurocrine Biosciences, Inc.*	12,079	1,335,937
Exelixis, Inc.*	34,137	1,260,338	Viartis, Inc.	145,587	1,268,063
Incyte Corp.*	19,286	1,167,767	Alkermes plc*	31,357	1,035,408
Argenx SE ADR*	1,953	1,155,912	Jazz Pharmaceuticals plc*	8,239	1,022,872
Halozyne Therapeutics, Inc.*	17,966	1,146,410	Protagonist Therapeutics, Inc.*	13,168	636,805
Moderna, Inc.*	39,698	1,125,438	Vaxcyte, Inc.*	16,618	627,496
Bridgebio Pharma, Inc.*	28,613	989,151	Ascendis Pharma A/S ADR*	3,534	550,809
Guardant Health, Inc.*	22,653	965,018	Madrigal Pharmaceuticals, Inc.*	1,488	492,870
TG Therapeutics, Inc.*	24,299	958,110	Agios Pharmaceuticals, Inc.*	16,450	481,985
Legend Biotech Corp. ADR*	28,093	953,196	Total Pharmaceuticals		16,221,546
Blueprint Medicines Corp.*	10,759	952,279	HEALTHCARE-PRODUCTS - 4.0%		
Revolution Medicines, Inc.*	26,754	946,021	Natera, Inc.*	12,303	1,739,767
BioNTech SE ADR*	10,369	944,201	Exact Sciences Corp.*	27,321	1,182,726
ADMA Biologics, Inc.*	43,818	869,349	Twist Bioscience Corp.*	14,516	569,898
Cytokinetics, Inc.*	20,961	842,423	Total Healthcare-Products		3,492,391
Ionis Pharmaceuticals, Inc.*	27,488	829,313	HEALTHCARE-SERVICES - 1.0%		
Roivant Sciences Ltd.*	81,405	821,376	Medpace Holdings, Inc.*	2,827	861,359
Axsome Therapeutics, Inc.*	6,919	806,963	Total Common Stocks		86,672,564
Sarepta Therapeutics, Inc.*	12,405	791,687	(Cost \$51,116,424)		
CRISPR Therapeutics AG* ¹	22,773	774,965			
PTC Therapeutics, Inc.*	13,828	704,675			
Ultragenyx Pharmaceutical, Inc.*	19,026	688,931			
Crinetics Pharmaceuticals, Inc.*	20,328	681,801			
SpringWorks Therapeutics, Inc.*	15,390	679,161			
Avidity Biosciences, Inc.*	22,941	677,218			
Amicus Therapeutics, Inc.*	74,384	606,973			
Veracyte, Inc.*	20,235	599,968			
Arcellx, Inc.*	9,039	592,958			
Apellis Pharmaceuticals, Inc.*	26,577	581,239			
Viking Therapeutics, Inc.*	24,057	580,977			
Summit Therapeutics, Inc.*	30,008	578,854			
ACADIA Pharmaceuticals, Inc.*	34,621	575,055			
Recursion Pharmaceuticals, Inc. — Class A* ¹	102,430	541,855			
Denali Therapeutics, Inc.*	36,601	497,591			
Nuvalent, Inc. — Class A*	6,993	495,944			
Beam Therapeutics, Inc.*	25,359	495,261			
Dynavax Technologies Corp.*	38,117	494,378			
Arrowhead Pharmaceuticals, Inc.*	37,085	472,463			

BIOTECHNOLOGY FUND

	SHARES	VALUE
SECURITIES LENDING COLLATERAL^{†,3} - 1.5%		
Money Market Fund^{***}		
First American Government		
Obligations Fund - Class X, 4.27% ⁴	1,265,702	\$ 1,265,702
Total Securities Lending Collateral		
(Cost \$1,265,702)		<u>1,265,702</u>
Total Investments - 101.8%		
(Cost \$53,146,126)		<u>\$ 88,702,266</u>
Other Assets & Liabilities, net - (1.8)%		<u>(1,602,073)</u>
Total Net Assets - 100.0%		<u>\$ 87,100,193</u>

* Non-income producing security.

*** A copy of each underlying unaffiliated fund's financial statements is available at the SEC's website at www.sec.gov.

[†] Value determined based on Level 1 inputs.

^{††} Value determined based on Level 2 inputs.

¹ All or a portion of this security is on loan at March 31, 2025.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7-day yield as of March 31, 2025.

ADR — American Depositary Receipt

plc — Public Limited Company